Mitochondrial dysfunction — impaired ATP production, increased reactive oxygen species, and defective mitophagy — is documented in aging, neurodegeneration, and metabolic disease. Several peptides have attracted research interest for their reported effects on mitochondrial function, and published research indexed on PubMed continues to track this area closely.
SS-31 (Elamipretide)
SS-31 concentrates in the inner mitochondrial membrane, where it interacts with cardiolipin — essential for organizing electron transport chain complexes. Published research reports SS-31 improving ATP production, reducing mitochondrial ROS, and protecting against ischemia-reperfusion injury. SS-31 has been studied in Phase I and Phase II trials for heart failure and Barth syndrome — making it one of the few peptides in this category with human safety data. See the SS-31 compound profile.
MOTS-c
MOTS-c is a mitochondria-derived peptide encoded by the mitochondrial genome — naturally produced by the body. Research published in Cell Metabolism (Lee et al., 2015) established MOTS-c as a regulator of metabolic homeostasis, reporting effects on insulin sensitivity and exercise performance in rodent models. Circulating MOTS-c levels decline with age in humans. See the MOTS-c compound profile.
Humanin
Humanin is another mitochondria-derived peptide originally identified as a neuroprotective factor in Alzheimer’s disease models. Research has examined humanin in apoptosis inhibition, insulin sensitivity, cardiovascular protection, and aging contexts. Humanin levels decline with age in human studies.
Mitochondrial-Derived Peptides: A Distinct Discovery Story
MOTS-c and Humanin belong to a category discovered through an unusual route: mitochondrial-derived peptides (MDPs), encoded not by nuclear DNA but by short open reading frames within mitochondrial DNA itself — specifically within the 16S rRNA region, which was long assumed to be non-coding. This discovery, made through bioinformatic and molecular biology work in the 2000s-2010s, effectively identified an entirely new class of endogenous signaling peptide that classical genome annotation had missed because mitochondrial DNA wasn’t expected to encode independently secreted signaling molecules. This is a genuinely interesting point of basic biology distinct from any specific therapeutic claim: MOTS-c and Humanin represent one of the more novel discoveries in peptide endocrinology in the past two decades, which is part of why they attracted substantial subsequent research interest.
Why Mitochondrial Function Research Matters Beyond Any Single Compound
The mitochondrial theory of aging holds that declining mitochondrial function — declining ATP output, rising oxidative stress, and impaired mitophagy (the cellular process that clears damaged mitochondria) — is a central driver of multiple age-related conditions rather than a downstream symptom of them. This theoretical framework is why MOTS-c, Humanin, and SS-31 (covered in a dedicated article on this site) are frequently discussed together despite acting through different specific mechanisms: they represent three different experimental approaches — a mitochondrial-genome-encoded signaling peptide, another mitochondrial-genome-encoded peptide with distinct receptor targets, and a synthetic cardiolipin-binding peptide, respectively — to the same underlying biological hypothesis.
Frequently Asked Questions
Are MOTS-c and Humanin proteins encoded by the same genes as other mitochondrial proteins?
No — they’re encoded by short reading frames within mitochondrial rRNA genes, a genuinely unusual discovery that expanded the known coding capacity of the mitochondrial genome beyond its traditional gene set.
Does age-related decline in circulating MOTS-c or Humanin levels prove they cause age-related mitochondrial decline?
No — this is a correlational observation. Whether restoring youthful levels of these peptides would reverse or slow associated changes is a separate causal question that current human data does not settle.
Which of these mitochondrial peptides has progressed furthest toward clinical use?
SS-31 (elamipretide) has advanced the furthest, with completed Phase I/II human trials in heart failure and Barth syndrome — see our dedicated SS-31 research overview for detail on that specific trial history and its outcomes.
Explore the full Peptide Research Hub for related research overviews.
Research reference only. Mitochondria-targeted peptides are investigational compounds. Not medical advice.
